Allakos Initiates Patient Recruitment for AK002 Registrational Studies
(World News Science)

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis -- -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that it is recruiting patients for two previously announced registrational clinical studies of AK002; a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Top-line safety...